A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
This study is testing a new experimental drug called MEN2312 to see how well it works against advanced breast cancer. It is a 'first-in-human' trial, meaning researchers are testing this drug in people for the first time to find the right dose and see if it can help stop tumor growth.
This trial is for adults with advanced breast cancer that has returned or spread and no longer responds to standard treatments. You must have specific genetic markers (PIK3CA, AKT1, or PTEN) and have previously been treated with hormone therapies and CDK4/6 inhibitors.
You will receive either the new drug (MEN2312) alone or in combination with another medication called elacestrant. The medical team will monitor you very closely with regular check-ups and tests to ensure the treatment is safe and to track how your cancer responds.
The study is currently recruiting patients at medical centers in Springdale, Arkansas, as well as Duarte and La Jolla, California. Please contact a study site near you to discuss the specific timeline for your participation.
- 1This is an early-stage study testing a new way to target specific genetic changes in breast cancer cells.
- 2Participants will receive high-level medical supervision and regular monitoring throughout the trial.
- 3Eligible participants must have specific genetic markers and previous experience with certain standard hormone and targeted therapies.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.